Spinal and Paraspinal Lesions: The Role of Stereotactic Body Radiotherapy

Author(s):  
Iris C. Gibbs
2018 ◽  
Vol 194 (5) ◽  
pp. 403-413 ◽  
Author(s):  
Eleni Gkika ◽  
Dominik Bettinger ◽  
Leo Krafft ◽  
Michael Schultheiss ◽  
Hannes Philipp Neeff ◽  
...  

2014 ◽  
Vol 9 (1) ◽  
Author(s):  
Pierina Navarria ◽  
Anna Maria Ascolese ◽  
Stefano Tomatis ◽  
Luca Cozzi ◽  
Fiorenza De Rose ◽  
...  

Sarcoma ◽  
2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Adam D. Lindsay ◽  
Edward E. Haupt ◽  
Chung M. Chan ◽  
Andre R. Spiguel ◽  
Mark T. Scarborough ◽  
...  

Background. The most common site of sarcoma metastasis is the lung. Surgical resection of pulmonary metastases and chemotherapy are treatment options that have been employed, but many patients are poor candidates for these treatments for multiple host or tumor-related reasons. In this group of patients, radiation might provide a less morbid treatment alternative. We sought to evaluate the efficacy of radiotherapy in the treatment of metastatic sarcoma to the lung. Methods. Stereotactic body radiotherapy (SBRT) was used to treat 117 pulmonary metastases in 44 patients. Patients were followed with serial computed tomography imaging of the chest. The primary endpoint was failure of control of a pulmonary lesion as measured by continued growth. Radiation-associated complications were recorded. Results. The majority of patients (84%) received a total dose of 50 Gy per metastatic nodule utilizing an image-guided SBRT technique. The median interval follow-up was 14.2 months (range 1.6–98.6 months). Overall survival was 82% at two years and 50% at five years. Of 117 metastatic nodules treated, six nodules showed failure of treatment (95% control rate). Twenty patients (27%) developed new metastatic lesions and underwent further SBRT. The side effects of SBRT included transient radiation pneumonitis n=6, cough n=2, rib fracture n=1, chronic pain n=1, dermatitis n=1, and dyspnea n=1. Conclusion. Stereotactic body radiotherapy is an effective and safe treatment for the ablation of pulmonary metastasis from sarcoma. Further work is needed to evaluate the optimal role of SBRT relative to surgery or chemotherapy for treatment of metastatic sarcoma.


2014 ◽  
Vol 23 (4) ◽  
pp. 1099-1103 ◽  
Author(s):  
Luluel Khan ◽  
Michael Tjong ◽  
Hamid Raziee ◽  
Justin Lee ◽  
Darby Erler ◽  
...  

2011 ◽  
Vol 11 (1) ◽  
pp. 7-15 ◽  
Author(s):  
A Needham ◽  
D Hutton ◽  
A Baker

AbstractLung stereotactic body radiotherapy (SBRT) is a novel and effective technique for the treatment of early stage non small cell lung cancer which is rapidly becoming the radiotherapy regime of choice for those patients unable or unwilling to undergo surgical resection.Although introduced almost 20 years ago, it was not until the wider establishment of image guided radiotherapy (IGRT) techniques that many UK departments first considered and then succeeded in implementing lung SBRT. Many have been assisted in this through membership of the national UK SBRT consortium which aims to facilitate local introduction and to provide guidelines and practical support for the wider radiotherapy community.This article will seek to place the introduction of SBRT within a broad historical context, outline basic principles for safe and effective practice and describe how such principles are currently being pursued in an era of IGRT. Additionally, the role of the UK SBRT consortium in implementation will be reported alongside the results of its first national survey on the subject.


Sign in / Sign up

Export Citation Format

Share Document